Literature DB >> 6802408

Additive antianginal effect of verapamil in patients receiving propranolol.

M Bassan, D Weiler-Ravell, O Shalev.   

Abstract

Ten men with stable angina pectoris not fully relieved by optimal doses of propranolol (mean 218 mg daily) were given a single oral dose of 120 mg verapamil or a placebo on alternate mornings; the order of treatment was double blind. Patients had trained in a protocol that precipitated angina after three to six minutes of exercise on a bicycle ergometer. On test days, and with continued propranolol treatment, bicycle exercise was performed just before the administration of verapamil or placebo and hourly thereafter for eight hours. Mean exercise tolerance was 118 seconds greater one hour after verapamil than one hour after placebo (p <0.001), and a significant though somewhat diminished difference of 66 seconds was still present at six hours (p <0.01). Verapamil lowered resting systolic blood pressure by 12 mm Hg (p <0.01) without changing heart rate. None of the 10 patients showed adverse effects from the verapamil-propranolol combination.The results of this study suggest that verapamil is a highly effective antianginal supplement to propranolol.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6802408      PMCID: PMC1497925          DOI: 10.1136/bmj.284.6322.1067

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  23 in total

1.  Reassessment of failed beta-blocker treatment in angina pectoris by peak-exercise heart rate measurements.

Authors:  G Jackson; L Atkinson; S Oram
Journal:  Br Med J       Date:  1975-09-13

Review 2.  Verapamil and the myocardium.

Authors:  W G Nayler; D Krikler
Journal:  Postgrad Med J       Date:  1974-07       Impact factor: 2.401

3.  Asystole after verapamil.

Authors:  M E Benaim
Journal:  Br Med J       Date:  1972-04-15

4.  Verapamil in cardiac arrhythmias.

Authors:  J R Milne; C B Boothby; C S Garrard; D Pickering
Journal:  Br Med J       Date:  1972-05-06

5.  Double blind evaluation of orally administered iproveratril in patients with angina pectoris.

Authors:  M Neumann; A A Luisada
Journal:  Am J Med Sci       Date:  1966-05       Impact factor: 2.378

6.  Propranolol and isosorbide dinitrate synergism in angina pectoris.

Authors:  H I Russek
Journal:  Am J Cardiol       Date:  1968-01       Impact factor: 2.778

7.  Importance of the design of an exercise protocol in the evaluation of patients with angina pectoris.

Authors:  D R Redwood; D R Rosing; R E Goldstein; G D Beiser; S E Epstein
Journal:  Circulation       Date:  1971-05       Impact factor: 29.690

8.  Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris.

Authors:  B Livesley; P F Catley; R C Campbell; S Oram
Journal:  Br Med J       Date:  1973-02-17

9.  Clinical evaluation of verapamil in angina pectoris.

Authors:  G Sandler; G A Clayton; S G Thornicroft
Journal:  Br Med J       Date:  1968-07-27

10.  Some effects of iproveratril (Isoptin) on the cardiovascular system.

Authors:  W G Nayler; I McInnes; J B Swann; J M Price; V Carson; D Race; T E Lowe
Journal:  J Pharmacol Exp Ther       Date:  1968-06       Impact factor: 4.030

View more
  5 in total

1.  Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.

Authors:  D L Murdoch; G D Thomson; G G Thompson; G D Murray; M J Brodie; G T McInnes
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 2.  Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Authors:  J N Lessem; B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

3.  Combination of metoprolol with molsidomine in the treatment of angina pectoris.

Authors:  J P van Mantgem; K I Lie; A W Matroos
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Lack of a pharmacokinetic interaction between nifedipine and the beta-adrenoceptor blockers metoprolol and atenolol.

Authors:  M J Kendall; D B Jack; S J Laugher; J Lobo; S Rolf Smith
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

5.  Tolerability of combined treatment with verapamil and beta-blockers in angina resistant to monotherapy.

Authors:  J C McGourty; J H Silas; S A Solomon
Journal:  Postgrad Med J       Date:  1985-03       Impact factor: 2.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.